Compare Glenmark Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FDC LTD. - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FDC LTD. GLENMARK PHARMA/
FDC LTD.
 
P/E (TTM) x 10.2 18.3 55.9% View Chart
P/BV x 1.5 2.5 59.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 GLENMARK PHARMA   FDC LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
FDC LTD.
Mar-18
GLENMARK PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs712319 223.1%   
Low Rs484164 294.9%   
Sales per share (Unadj.) Rs349.661.6 567.2%  
Earnings per share (Unadj.) Rs32.89.9 329.5%  
Cash flow per share (Unadj.) Rs44.312.0 370.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.673.2 271.5%  
Shares outstanding (eoy) m282.17174.40 161.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.73.9 43.6%   
Avg P/E ratio x18.224.3 75.1%  
P/CF ratio (eoy) x13.520.2 66.8%  
Price / Book Value ratio x3.03.3 91.1%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62542,118 400.4%   
No. of employees `00012.05.5 217.6%   
Total wages/salary Rs m20,5612,167 948.9%   
Avg. sales/employee Rs Th8,196.01,943.7 421.7%   
Avg. wages/employee Rs Th1,708.1391.7 436.0%   
Avg. net profit/employee Rs Th768.5313.7 245.0%   
INCOME DATA
Net Sales Rs m98,65510,751 917.7%  
Other income Rs m2,081510 408.4%   
Total revenues Rs m100,73611,260 894.6%   
Gross profit Rs m15,8582,267 699.6%  
Depreciation Rs m3,259351 927.5%   
Interest Rs m3,34614 23,899.3%   
Profit before tax Rs m11,3352,411 470.1%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756671 559.7%   
Profit after tax Rs m9,2501,735 533.1%  
Gross profit margin %16.121.1 76.2%  
Effective tax rate %33.127.8 119.1%   
Net profit margin %9.416.1 58.1%  
BALANCE SHEET DATA
Current assets Rs m66,9687,213 928.5%   
Current liabilities Rs m40,2112,104 1,911.4%   
Net working cap to sales %27.147.5 57.1%  
Current ratio x1.73.4 48.6%  
Inventory Days Days8354 152.9%  
Debtors Days Days8128 292.9%  
Net fixed assets Rs m33,3226,865 485.4%   
Share capital Rs m282175 161.1%   
"Free" reserves Rs m55,77012,586 443.1%   
Net worth Rs m56,05212,761 439.2%   
Long term debt Rs m35,7386 595,625.0%   
Total assets Rs m132,88815,041 883.5%  
Interest coverage x4.4173.2 2.5%   
Debt to equity ratio x0.60 135,603.6%  
Sales to assets ratio x0.70.7 103.9%   
Return on assets %9.511.6 81.5%  
Return on equity %16.513.6 121.4%  
Return on capital %17.819.0 94.0%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9981,889 3,335.3%   
Fx outflow Rs m22,8590-   
Net fx Rs m40,1401,889 2,125.1%   
CASH FLOW
From Operations Rs m13,2421,498 883.7%  
From Investments Rs m-6,990201 -3,475.8%  
From Financial Activity Rs m-7,387-1,694 436.0%  
Net Cashflow Rs m-2,97110 -28,842.7%  

Share Holding

Indian Promoters % 48.3 68.9 70.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.7 146.8%  
FIIs % 34.4 7.5 458.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.0 55.3%  
Shareholders   56,727 23,730 239.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  CADILA HEALTHCARE  SUN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

NARAYANA HRUDAYALAYA LTD Surges by 6%; BSE HEALTHCARE Index Down 0.6% (Market Updates)

Nov 11, 2019 | Updated on Nov 11, 2019

NARAYANA HRUDAYALAYA LTD share price has surged by 6% and its current market price is Rs 290. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 5.5%) and FDC LTD. (up 5.8%). The top losers are SUVEN LIFESCIENCES and JUBILANT LIFE SCIENCES .

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS